The estimated Net Worth of Mario Germano Mgg Strategic... is at least 646 百万$ dollars as of 16 September 2022. Mario Strategic owns over 387,171 units of Royalty Pharma plc stock worth over 629,434,101$ and over the last 2 years Mario sold RPRX stock worth over 16,102,442$.
Mario has made over 1 trades of the Royalty Pharma plc stock since 2022, according to the Form 4 filled with the SEC. Most recently Mario sold 387,171 units of RPRX stock worth 16,102,442$ on 16 September 2022.
The largest trade Mario's ever made was selling 387,171 units of Royalty Pharma plc stock on 16 September 2022 worth over 16,102,442$. On average, Mario trades about 387,171 units every 0 days since 2022. As of 16 September 2022 Mario still owns at least 22,657,815 units of Royalty Pharma plc stock.
You can see the complete history of Mario Strategic stock trades at the bottom of the page.
Over the last 4 years, insiders at Royalty Pharma plc have traded over 863,995,127$ worth of Royalty Pharma plc stock and bought 5,330,350 units worth 152,553,456$ . The most active insiders traders include David C Hodgson、William E Ford、Capital Partners Gp, L.L.C..... On average, Royalty Pharma plc executives and independent directors trade stock every 13 days with the average trade being worth of 7,420,205$. The most recent stock trade was executed by Rory B Riggs on 2 January 2024, trading 470,000 units of RPRX stock currently worth 13,221,100$.
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Royalty Pharma plc executives and other stock owners filed with the SEC include: